News

ALK’s ACARIZAX® Tablet Gains NICE Approval in the UK

ALK’s ACARIZAX® Tablet Gains NICE Approval in the UK

ALK’s ACARIZAX® Tablet Gains NICE Approval in the UK

ALK (ALKB:DC / OMX: ALK B / AKBLF) recently announced significant news regarding its ACARIZAX® tablet, which has been recommended by the National Institute for Health and Care Excellence (NICE). This recommendation opens the door for patients suffering from persistent, moderate to severe house dust mite allergic rhinitis to receive ACARIZAX® through the National Health Service (NHS) in England, Wales, and Northern Ireland. Consequently, this makes the treatment eligible for general reimbursement, benefiting countless individuals affected by this condition.

First Sublingual Allergy Immunotherapy to Gain Approval

ACARIZAX® holds the distinction of being the first sublingual allergy immunotherapy (AIT) product that NICE has assessed and endorsed. This pivotal development signifies its widespread availability within the NHS framework. As of now, the UK remains one of the few European markets where ALK’s allergy tablets lack adequate public reimbursement, highlighting a significant gap that this recommendation is poised to fill. Moreover, allergic immunotherapy is generally underutilised in the UK compared to other European nations, making this milestone even more critical.

NICE Approval a Landmark Moment

ALK’s Executive Vice President of Commercial Operations, Søren Niegel, expressed his enthusiasm about the approval: “Today’s news marks a milestone for ALK. NICE’s methodologies and guidelines are widely regarded as the gold standard, and we are proud to be the first and only company offering sublingual allergy immunotherapy tablets across the United Kingdom for the many patients whose lives are profoundly affected by allergies.” This endorsement reflects the growing recognition of allergenic conditions and the necessity of effective treatment.

The Prevalence of Allergic Rhinitis

Allergic rhinitis is a common concern in the UK, impacting approximately 26% of adults. For many of these individuals, house dust mites are identified as the most prevalent airborne allergens. It is estimated that nearly half of those suffering from allergic rhinitis—over 5 million individuals—are affected by dust mite allergies. Unfortunately, despite the availability of various symptomatic treatments, around one million people endure debilitating and uncontrolled symptoms that significantly diminish their quality of life.

NICE’s Review Process and Future Directions

NICE plays a crucial role in evaluating the clinical benefits and cost-effectiveness of healthcare interventions. They published a Final Draft Guidance document detailing the assessment of ACARIZAX® as an effective treatment option for uncontrolled house dust mite allergies. Following this, a Final Guidance publication is anticipated, following which NHS systems in England, Wales, and Northern Ireland will implement ACARIZAX® in their treatment practices. Alongside this, ALK aims to submit another application for a NICE review of its sublingual tree tablet, ITULAZAX®, and is also looking to expand approvals for both ACARIZAX® and ITULAZAX® to include treatments for children.

Current Focus and Future Growth

ALK’s operations in the UK currently emphasize anaphylaxis treatments, notably through its adrenaline pen Jext®, which is on the market, and a nasal spray called EURneffy®, slated for launch pending regulatory approval. Although the sales of AIT tablets are modest, ALK anticipates fostering synergies between its anaphylaxis products and its allergy tablets as awareness grows and infrastructure expands. These efforts are designed to bolster access and enhance overall treatment options for patients.

Looking Ahead After NICE Approval

While the NICE approval is a landmark achievement for ALK, it is not projected to influence the company's revenue growth immediately. However, the potential for increased patient access to ACARIZAX® may lead to long-term benefits.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Maiken Riise Andersen, tel. +45 5054 1434

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergies and those who treat allergies. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 individuals globally and is listed on Nasdaq Copenhagen. More information can be found at www.alk.net.

Frequently Asked Questions

What is ACARIZAX®?

ACARIZAX® is the first sublingual allergy immunotherapy tablet recommended by NICE for treating moderate to severe house dust mite allergic rhinitis.

How does this NICE recommendation benefit patients?

This recommendation allows patients to access ACARIZAX® through the NHS, making it eligible for reimbursement and improving treatment options.

What is the prevalence of allergic rhinitis in the UK?

Approximately 26% of adults in the UK are affected by allergic rhinitis, with house dust mites being a leading cause.

What are the next steps following the NICE approval?

NICE plans to publish a Final Guidance, after which ACARIZAX® will be implemented in NHS treatment practices.

What other products does ALK offer?

ALK also offers an adrenaline pen for anaphylaxis (Jext®) and plans to launch a nasal spray (EURneffy®). Additionally, they are pursuing further immunotherapy tablets for broader indications.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 323

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 247

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 278

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 312

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 522

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 371

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 44

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 238

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 495

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 265

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Valneva Faces Setback as Ixchiq Vaccine License Suspended

Updated Category News Views 213

Valneva SE's Ixchiq Vaccine Under Scrutiny Valneva SE stock (VALN) experienced a decline recently after the U.S. Food and Drug Administration (FDA) announced the suspension of its license for the Ixchiq vaccine. This decision stems from reports of serious adverse events (SAEs) linked to chikungunya-like illness, leading to concerns about the vaccine's safety profile....

Continue Reading
Tetra Tech Secures Major Water Management Deal Worth £800 Million

Updated Category News Views 114

Tetra Tech Selected for £800 Million Water Management Framework In a significant development, Tetra Tech, Inc. (NASDAQ: TTEK), a prominent provider of advanced consulting and engineering services, has been awarded a major contract by Northern Ireland Water. This framework agreement, valued at up to £800 million, aims to bolster the sustainable delivery of essential...

Continue Reading
Synedgen Secures $2.2 Million JWMRP Grant for MIIST305

Updated Category News Views 119

Synedgen Achieves Major Milestone with JWMRP Funding Synedgen, Inc., a prominent biotechnology firm, is making headlines with its recent announcement about receiving a substantial $2.2 million contract from the Joint Warfighter Medical Research Program (JWMRP). This funding is designated for the advancement of MIIST305, a pioneering therapeutic aimed at shielding...

Continue Reading
Ensurge Micropower ASA Expands Private Placement Opportunities

Updated Category News Views 210

Ensurge Micropower ASA Extends Private Placement Bookbuilding Ensurge Micropower ASA has recently made waves in the investment community with an update on its ongoing private placement. The company is taking strategic steps to extend the bookbuilding period, offering investors increased opportunities to participate. The update was shared following a stock exchange...

Continue Reading
Dale Hageman Takes Leadership Role as ESAC Board Chairman

Updated Category News Views 130

Dale Hageman to Lead ESAC Board as Chairman Spirit HR is proud to share that its CEO and Founder, Dale Hageman, has been elected Chairman of the Board for the Employer Services Assurance Corporation (ESAC). This leadership role reflects Dale’s long-standing dedication to the HR field and his steady commitment to the highest levels of financial assurance and...

Continue Reading